JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
Executive Summary
A few months after the release of AstraZeneca's widely heralded JUPITER Crestor study, physicians seem prepared to prescribe statins more broadly based on that evidence, according to discussion at the American College of Cardiology annual meeting
You may also be interested in...
Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs
Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.
One Payer's Perspective On CER: WellPoint Wants Real-World Applicability
A key component in the current thinking on comparative effectiveness research is an understanding of how medical treatments are used in real-world settings. From the perspective of one major payer, WellPoint, staying on this course would be a good thing
One Payer's Perspective On CER: WellPoint Wants Real-World Applicability
A key component in the current thinking on comparative effectiveness research is an understanding of how medical treatments are used in real-world settings. From the perspective of one major payer, WellPoint, staying on this course would be a good thing